Mabion S.A. (FRA:272)
Germany · Delayed Price · Currency is EUR | Market Cap | 28.26M |
| Revenue (ttm) | 2.65M |
| Net Income (ttm) | -15.29M |
| Shares Out | n/a |
| EPS (ttm) | -0.95 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Average Volume | n/a |
| Open | 1.734 |
| Previous Close | 1.722 |
| Day's Range | 1.734 - 1.734 |
| 52-Week Range | 1.722 - 2.840 |
| Beta | n/a |
| RSI | 33.50 |
| Earnings Date | Nov 25, 2025 |
About Mabion
Mabion S.A., a biopharmaceutical company, provides services as a contract development and manufacturing organization in the process development, analytics, and manufacturing of biologic medicines in Poland. It offers drug substance manufacturing, fill and finish, gene to vial end-to-end development, process development, analytics, and banking services. In addition, it offers cell line development, process development, production of a product for preclinical and clinical trials, development and validation of analytical methods, and preparation o... [Read more]
News
Spark Therapeutics Further Strengthens Technical Expertise with Appointment of Cynthia Pussinen as Chief Technical Officer
PHILADELPHIA, Feb. 25, 2021 (GLOBE NEWSWIRE) -- Spark Therapeutics, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) and a fully integrated, commercial gene therapy company dedicated to challe...
Spark Therapeutics Announces First Participant Dosed in Phase 1/2 Study of Investigational Gene Therapy for Late-Onset Pompe Disease
First participant dosed in the RESOLUTE SM trial, a Phase 1/2 dose-escalation study of SPK-3006
GAMCO Investors Exits Viacom, Spark Therapeutics
Mario Gabelli (Trades, Portfolio)’s firm GAMCO Investors sold shares of the following stocks during the fourth quarter of 2019.
Regulators Give Roche Green Light For $4.3B Spark Therapeutics Acquisition
Roche Holding (OTCQX: RHHBY) has received approval from the Federal Trade Commission and Britain’s Competition and Markets Authority to acquire Spark Therapeutics, Inc.
Roche to complete $4.3 billion Spark deal as regulators give all clear
Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competitio...
U.S. antitrust enforcers give Roche approval to buy Spark Therapeutics
Swiss drugmaker Roche has won U.S. antitrust approval for its $4.3 billion deal to buy gene therapy specialist Spark Therapeutics , the Federal Trade Commission said on Monday, clearing the way for t...
Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product
PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, t...
FTC staff recommends approval of Roche deal for Spark: report
The Federal Trade Commission staff reviewing Roche's plan to buy U.S.-based gene therapy specialist Spark Therapeutics for $4.3 billion recommended that the deal be approved without requiring any as...
Paralympic Skier Danelle Umstead Teams Up with Spark Therapeutics to Help People Living with Inherited Retinal Diseases (IRDs) Access Genetic Testing
Paralympic, blind skier declared Eye Want 2 Know® and pursued genetic testing to uncover the genetic cause of her retinitis pigmentosa (RP), an IRD
Roche, Spark again extend $4.3 billion takeover offer
Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue.
Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders
PHILADELPHIA, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, a...
Roche, Spark extend $4.3 billion takeover again, this time to September 3
Roche and Spark Therapeutics announced another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews in the United States and Brit...
Roche, Spark push back takeover deadline in $4.3 billion deal
Swiss drugmaker Roche has agreed to extend the takeover deadline in its $4.3 billion bid for U.S. gene therapy specialist Spark Therapeutics , adding it remains "fully committed" to the transaction a...
The 5 Most Expensive Drugs In US: What You Should Know
The upward trajectory of prescription drug prices in the U.S. has drawn the ire of lawmakers.
Why Coeur Mining, Spark Therapeutics, and Tandem Diabetes Care Slumped Today
Find out what made these stocks miss out on a rally.
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Roche says its $4.3 billion offer for Spark is still on track for June completion
Roche said its effort to expand in gene therapy via the $4.3 billion takeover of Spark Therapeutics remained on track despite failing to get enough votes to clinch the deal and as U.S. regulators cont...
There will be continued interest in gene therapy, says biotech analyst
CNBC's "Power Lunch" team discusses whether there's more biotech buyouts ahead with Michael Yee of Jefferies.
Technician: It's time to fade the biotech rally
Cornerstone Macro's Carter Worth on whether there's a biotech breakdown ahead. With CNBC's Melissa Lee and the Fast Money traders, Tim Seymour, Brian Kelly, Dan Nathan and Guy Adami.
Spark Therapeutics CEO on breakthroughs in gene therapy
effrey Marrazzo, Spark Therapeutics CEO, joins 'Squawk Box' to discuss how his company is making breakthroughs in gene therapy and the fight to cure hemophilia.
Spark's hemophilia gene therapy reduced bleeds by 97% trial
CNBC's Meg Tirrell reports on the latest data out of Spark Therapeutics' hemophilia gene therapy trial.